CloudBlue and CloudSense Strike a Strategic Relationship to Connect Telecommunications Providers With a Broad Ecosystem of ICT Channel Partners via a New Digital Catalog
5.4.2022 16:00:00 EEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company which powers some of the largest commerce platforms for cloud and IT channel products globally, today announced an agreement with CloudSense, provider of one of the market’s most powerful Configure, Price, Quote (CPQ) platforms.
CloudSense has a well-established footprint within the telecommunications industry, with customers including prominent regional and international brands such as BT, Starhub and Vodafone Ziggo. By providing a direct integration from CloudBlue Connect™ to the CloudSense CPQ platform, CloudSense’s community of telecommunications customers will be able to tap into a new pool of ICT offerings and scale their business faster than ever.
The direct integration between CloudBlue Connect and CloudSense CPQ will allow telecommunications providers to enrich their own portfolio of B2B solutions more efficiently. This new integration will streamline their ability to procure traditional ICT services and bundle them into a wide range of innovative B2B XaaS solutions, which can be sold by a direct sales force or a network of resellers. Telecommunications and ICT providers will be able to create simple and easy quotes and contracts via CloudSense CPQ without the need to rekey orders or engage in manual processes.
CloudBlue will benefit from this new relationship through expanded exposure of its 200+ XaaS digital solutions to the telecommunications community. The initiative clears the way for CloudSense’s customers to access the tools they need to provide businesses of all sizes with the anything-as-a-service (XaaS) offerings that have surged in demand post-pandemic.
“As telcos look for new ways to diversify their offerings, cross-platform integration becomes key to providing end-users the best in Cloud. CloudBlue’s new agreement with CloudSense marks the latest in a series of innovative and creative relationships forming across Cloud to the continued delight of channel partners,” said Tarik Faouzi, senior vice president of CloudBlue.
“CloudSense recognizes the importance of bringing to market innovative solutions that address challenges in our focus verticals. We believe the CloudSense-CloudBlue agreement establishes the first Marketplace of its kind to facilitate commercial innovation across the communications ecosystem. This will give communications service providers broader access to a global network of channel partners and remove the need for manual input when drafting quotes and contracts,” said Jonathan English, CEO, CloudSense.
About CloudSense
The CloudSense Configure, Price, Quote (CPQ) application suite powers increased productivity and profits for ambitious enterprises allowing them to launch faster, sell more and fulfill orders faultlessly. Its growing global community of customers rely on CloudSense to deliver sales transformation within the Communications and Media industries. Leading brands including Telefonica, Telstra, and Informa use CloudSense's portfolio of applications to streamline the entire customer lifecycle, providing a better customer experience while improving business performance. To find out more, visit CloudSense.com
About CloudBlue
CloudBlue helps businesses succeed in the as-a-service economy and accelerate time to revenue by managing subscription and billing, vendor and product information, and partner onboarding across multiple channels. Through its leading ecosystem orchestration platform, CloudBlue enables companies to create their own ecosystems, as well as connect vendor and go-to-market ecosystems, automating the distribution of traditional and digital products and services across partners in the digital supply chain. CloudBlue serves more than 180 companies around the globe and powers the world’s largest cloud B2B marketplaces, which represent 30 million B2B cloud subscriptions. Learn more about CloudBlue at www.cloudblue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005045/en/
Contact information
Andrew Zelinko
CloudBlue
Andrew.Zelinko@cloudblue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom